title: Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
authors.affiliation: St. Boniface Hospital Department of Medicine, Manitoba Cancer Treatment & Research Foundation, Kingston, ON, Canada.
authors.forename: B
authors.initials: B
authors.lastname: Weinerman
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: W
authors.initials: W
authors.lastname: Mertens
authors.forename: I
authors.initials: I
authors.lastname: Tannock
authors.forename: P
authors.initials: P
authors.lastname: Venner
authors.forename: R
authors.initials: R
authors.lastname: Spaulding
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D013453:Sulfonylurea Compounds; C058179:sulofenur